Granules India Limited has informed the Exchange regarding a press release dated January 30, 2025, titled "Granules Strengthens ADHD Portfolio with FDA Approval for Lisdexamfetamine Dimesylate Capsules".
Press Release Jan 30 2025
Filed with NSE · · 3 pages · English
Watch Granules India's latest callGranules India (NSE:GRANULES) Q2 2027 Earnings Call · Replay · Nov 2Read the transcript of Granules India (NSE:GRANULES) Q2 2027 Earnings CallRelease
Earlier from Granules India
- Press Release Jan 24 2025
- Press Release Dec 17 2024
- Granules India Confirms USFDA Classification Does Not Impact Ongoing Operations, Assures Commitment to Compliance and Growth
- Press Release Nov 27 2024
- Press Release Nov 14 2024
Later from Granules India
- Press Release Feb 21 2025
- Granules India enters CDMO business by acquiring Senn Chemicals AG
- Press Release Apr 10 2025
- Granules India Announces Closing of Acquisition of Senn Chemicals, Strengthening Capabilities in Peptide Therapeutics and CDMO Services
- Deal Ticker: Granules India Acquires Senn Chemicals AG
Follow Granules India into a list and get an email when it puts out news.
Follow Granules India